Parkinson’s Disease

Published Date : Aug 2023
Category : Mental Health Disorders
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Recognize the Opportunities in the Parkinson’s Disease Market through DiseaseLandscape Insights Services

Reshaping Parkinson’s Disease Market: Where Services Meet Successful Implementation”

How and why the dopamine-secreting neurons do not work properly in Parkinson’s patients? Let’s explore the domain of global Parkinson’s Disease with the help of research done by DiseaseLandscape Insights.

Parkinson’s Disease (PD) is the second most common neurodegenerative illness which has become a major public health issue because of growing awareness about psychosocial consequences and socioeconomic impacts. Common clinical symptoms include movement-related bradykinesia, resting tremor, muscle rigidity, postural instability developing, etc.

The potential causes of the disease are oxidative damage, environmental pollutants, genetic factors, and accelerated aging. Approximately 10 to 20% of Parkinson’s Disease cases are linked to a genetic cause, which is either autosomal dominant or autosomal recessive. However, many Parkinson's patients are classified as idiopathic, which means the patients are suffering from unknown cause.

Based on the NIH data, the incidence rate for Parkinson’s Disease is 4% for the age group of people below 50 years, whereas 0.5-1% for the age group of 65-70 years old, and 1-3% for the people 80 years and above. With an aging population, the prevalence and incidence rate for Parkinson’s Disease is increasing by more than 30%, resulting in both direct and indirect costs to society and the economy.

According to the study done by Parkinson’s Foundation in the year 2022, nearly 90,000 people were diagnosed with Parkinson’s Disease in the United States. Additionally, the DLI study states that disability and death related to PD are increasing at a faster pace globally than any other neurological condition. For instance, in the last 25 years, the prevalence of Parkinson’s Disease becomes doubled and approximately 8.5 million people are suffering from Parkinson’s Disease worldwide. Moreover, it is proven that Parkinson’s Disease affects men 1.5 times more frequently than women.

As a result of the growing prevalence rate, the demand for therapeutic products is rising significantly for symptomatic treatment across the globe.  Thus, to reduce the disease burden, launching new products for accurate and early diagnosis of PD has been considered an essential part of the global economy. This creates a bundle of opportunities for the market players.

DiseaseLandscape Insights aid in making knowledgeable choices in the field of healthcare equipment, therapies, and diagnostics, where diverse technologies and developments will drive business expansion.

Diagnostic Analysis-

" Diagnostic Advancements for Parkinson’s Disease: Empowering Patient Care"

According to NIH, Parkinson’s Disease (PD) is incorrectly diagnosed in 6 to 25% of cases at specialized movement disorder centres. However, the global Parkinson’s Disease diagnostic market is booming because various research projects are developing precise and accurate diagnostic techniques and tests. Below are the prominent diagnostic categories that contribute significantly to the market depending on various factors such as the medical history, symptoms of a patient, neurological exams, genotype, age, and the advancements in diagnostic technologies.

  1. Imaging tests

    - The imaging tests are used to take images of the patient’s brain. It has the potential to improve differential diagnostic accuracy. The types of imaging tests used for Parkinson’s disease are as follows:
  • Magnetic Resonance Imaging-

    MRI is utilized to detect characteristics that may indicate secondary rather than primary Parkinsonism, such as significant small vessel ischemic alteration. Recent ultra-high-field MRI (7 T) experiments have yielded promising findings in terms of sensitivity and specificity.
  • Dopamine Transporter Scan-

    Dopamine transporter scan is a more practical, less costly, and generally available method for the diagnosis of PD. Additionally, DaTscan has been approved by the FDA to distinguish between essential tremors and Parkinson’s Disease.
  1. Laboratory tests

  • SYNTap-

    It is a seed amplification assay that scans the cerebrospinal fluid which surrounds the brain and spinal cord for misfolded alpha-synuclein proteins. The disease identification rate with the help of seed amplification assay is 87.7% among the people suffering from PD. The commercial introduction of the SYNTap test was announced by Amprion in October 2021.
  • SYN ONE Test-

    A skin biopsy test called the SYN ONE test analyses the skin, particularly the nerves, to help identify whether alpha-synuclein has a particular defect that could increase the chance of developing Parkinson's disease. It has a 95% sensitivity and 99% specificity and was created by CND Life Sciences.

The Parkinson's diagnostics industry is highly competitive, and several significant companies account their inputs for the growth and development of various diagnostic products. The following table highlights the names of market competitors who are contributing to the Parkinson’s disease market with their advanced diagnostic discoveries:

Diagnostic Market Players

Imaging Tests

Laboratory Tests

Fujifilm Holdings

Johnson & Johnson

GE Healthcare

Novartis AG

Siemens Healthcare

Abbott Laboratories

Philips Healthcare

Medtronic PLC

Shimadzu Corporation

Baxter International

Toshiba Medical Systems Corporation

Danaher Corporation

Carestream Health

General Electric

Hitachi Medical Corporation

Allergen PLC


Diagnostic Products

Imaging Products

Laboratory Test Products








Parkinson’s Disease Treatment Analysis

"A Pain-Free Life is Achievable: Comprehensive Treatment Evaluation for Parkinson’s Disease."

One of the main drivers for the growth of the global Parkinson’s Disease treatment market is escalating development of various technologies and drugs like levodopa for accurate treatment. Selection of treatment varies from person to person, based on their symptoms and the effectiveness of certain treatments, activity level, cost, and patient preferences treatments. The treatment options used for Parkinson’s disease are as follows-

  1. Medication-

    Medications are the primary way to treat symptoms of PD. Medications used in the treatment of Parkinson’s Disease are given below.
  • Carbidopa-levodopa-

    Levodopa and its combination therapy are the most efficient treatments available for PD. Levodopa acts as a precursor of dopamine and that is why it is used as a dopamine replacement agent. It shows lesser side effects than the other drugs. Even if the medicine is no longer administered, levodopa halts the progression of Parkinson’s disease or has more positive effects. It is the reasonable treatment option available to the PD patients.
  • Dopamine Agonists-

    Dopamine agonists act as a substitute for dopamine in the brain and have a comparable but lesser impact than levodopa. Dopamine agonists are used in the early stages of Parkinson’s Disease as a monotherapy.
  • Monoamine Oxidase-B Inhibitors-

    These inhibitors raise dopamine levels by inhibiting the effects of chemical or enzyme that breaks down dopamine (monoamine oxidase-B). These drugs can be used alone or in combination with other drugs in the early stages of the disease.
  • Catechol-O-methyltransferase Inhibitors

    - This is a first-line technique used for the treatment of PD and is known as an adjunct therapy for PD. These inhibitors help to block the enzyme COMT from breaking down levodopa. The two most common medications in this family are entacapone (Comtan) and opicapone (Ongentys).
  • Amantadine-

    Amantadine (Gocovri) alone may be prescribed to relieve the symptoms of mild, early-stage Parkinson’s Disease. According to the World Health Organization, amantadine alone is not effective to treat late-stage Parkinson’s Disease, although it is used as a combination therapy with levodopa.
  • Adenosine receptor antagonists (A2A receptor antagonists)-

    These medications target brain locations that govern dopamine response and allow more dopamine to be released. Istradefylline (Nourianz) is an A2A antagonist medication.
  • Nuplazid (Pimavanserin)-

    This medication is used to treat hallucinations and delusions caused by Parkinson’s Disease. Pimavanserin is administered orally in the form of two 17-mg pills once a day.
  1. Surgery

Surgery for Parkinson’s Disease is usually chosen for people who respond to treatments but have intolerable side effects. However, patients with late Parkinson’s Disease show various side effects which are unbearable, and surgery becomes a necessity for them.

  • Deep brain stimulation-

    People with severe Parkinson’s Disease who have unstable responses to levodopa are most likely candidates for deep brain stimulation. DBS can lessen or eliminate involuntary movements known as dyskinesia, as well as diminish tremor, rigidity, and instability.

Focused Ultrasound: A Novel Treatment in Development for Parkinson’s Disease with Tremor.

Focused ultrasound technology is being developed by the University of North Carolina at Chapel Hill School of Medicine, which is also in charge of a clinical trial to show how the therapy improved Parkinson's patients' motor impairment. The study was published in February 2023. The therapy also aims to address dyskinesias, twitches, and jerks, observed in some Parkinson’s Disease patients who have been on the oral treatment of levodopa for a long time.

The prevalence of Parkinson’s Disease has increased due to various risk factors. This led to the growth in the research field for discovering novel medications to prevent and manage the disease. Despite all innovations currently, there is no effective treatment available for Parkinson’s disease. There are many opportunities for the market players in discovering the new treatment plan for the disease.

Drug manufacturers for neurodegenerative diseases will get precise knowledge and insights from DiseaseLandscape Insights to improve the treatment industry. With our detailed analysis of treatment choices, novel technology, product inventories, and market players, we empower you to stay one step ahead of the competition.

The worldwide Parkinson's Disease market is extremely competitive and continuously growing. The market leaders listed below are redefining the landscape and pushing innovations in the search for better health outcomes.

Treatment Analysis

Manufacturer Name

Drug Name

Side Effects

Wockhardt Limited (Merind)

Carbidopa-levodopa (Lodosyn)

Orthostatic hypotension

Wockhardt Limited (Merind)

Inhaled Carbidopa-levodopa (Inbrija)

Nausea or light headedness

Boehringer Ingelheim

Pramipexole (Mirapex ER)

Hallucinations, sleepiness, hypersexuality, gambling, and eating.

Oceanic Pharmachem Pvt. Ltd

Rotigotine (Neupro)

Hallucinations, sleepiness, hypersexuality, gambling, and eating.


Apomorphine (Apokyn)

Hallucinations, sleepiness, hypersexuality, gambling, and eating.


Selegiline (Zelapar)

Headaches, nausea, or insomnia

Teva Pharmaceutical Industries, Ltd.

Rasagiline (Azilect)

Headaches, nausea, or insomnia

Newron Pharmaceuticals

Safinamide (Xadago)

Headaches, nausea, or insomnia

Orion Pharma

Entacapone (Comtan)

Dyskinesia, diarrhea, nausea, or vomiting

Portuguese pharmaceutical group BIAL

Opicapone (Ongentys)

Dyskinesia, diarrhea, nausea or vomiting

Dr. Reddy's Laboratories

Benztropine (Cogentin)

Memory loss, confusion, hallucinations, constipation, dry mouth, and poor urination

Adamas Pharmaceuticals

Amantadine (Gocovri)

Ankle swelling, change in skin color, or hallucinations.

Kyowa Kirin

Istradefylline (Nourianz)

Diarrhea, nausea or vomiting

Acadia Pharmaceuticals Inc

Nuplazid (Pimavanserin)

Nausea or light-headedness


Services Provided by DiseaseLandscape Insights in the Continuously Expanding Parkinson’s Disease Market.

" Transforming Data into Opportunities to Establish the Parkinson’s Disease-Free Population Pool”.

DiseaseLandscape Insights help to develop and set up commercial Parkinson’s Disease services for market players. DLI assists players by providing market analysis of product launch expansion, research & development in the field of drug discovery and clinical trial phases. DLI provides services in the placement of resources, risk evaluation, and safety of drugs, as well as insights for long-term planning into disease dynamics.

Additionally, DLI offers data for clinical and drug safety, medication-related papers, as well as regulatory body-related documents. Stakeholders can access journal articles, publication abstracts, marketing materials, and the websites of major medical organizations to discover even more data related to various preventive actions to be alert and clear.

Regulatory Framework for Parkinson’s Disease-

“Regulatory Compliance: The Key to a Successful Business Environment”

DiseaseLandscape Insights simplifies the regulatory criteria from several nations for Parkinson’s Disease. DLI delivers empirical findings regarding risk assessment, monitoring, and regulatory framework. Organizations and market participants can prevent, manage and react to Parkinson's flare-ups and protect the safety of affected people by exploring the DiseaseLandscape Insights services.

However, in May 2022 the World Health Assembly approved the Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031. The action plan will address worldwide concerns and gaps in care and services for people with Parkinson’s Disease (PD) and provide a comprehensive, coordinated response across sectors.

Moreover, for a better understanding of Parkinson’s Disease, the WHO has announced brief technical information guidelines called “Parkinson disease: a public health strategy” for policymakers, health program administrators and planners, health-care professionals, researchers, people with PD, caregivers, and other stakeholders. It emphasizes the critical intervention areas in Parkinson’s Disease, such as global health policies engaged in prevention and risk reduction, education and awareness, and access to treatment and care at various levels of the health system.

Competitive Analysis-

"Releasing Industry Opportunities: Analysing the Competitive Landscape of the Parkinson's Disease Market."

To fulfil the increased need for early detection and boost their competitive position, leading global firms have been researching new product introductions. In addition, they are pursuing growth tactics, which largely involve regulatory approvals, acquisitions, partnerships, portfolio expansion, etc.

For instance, competitors like Cure Parkinson's company revealed to start the world’s first phase 3 clinical trial for a cough drug called ambroxol in 2023 for the treatment of Parkinson’s Disease. New drug development by the market players is increasing the awareness about the product among the global population which further fuels the competition for novel drug innovation.

Additionally, Insightec introduced the Exablate technology in November 2021. It is for the treatment of tremor-dominant Parkinson’s Disease and of additional movement problems associated with Parkinson’s Disease, such as mobility, rigidity, and dyskinesia.

DiseaseLandscape Insights helps the industry player by providing intense knowledge about the strategies and revenue generation of existing market players which supports their decision-making framework.

Market Trends Analysis-

“Analyse the Market's Shifting Trends for Parkinson’s Disease to Stay Apprised.”

The global market is continuously expanding because manufacturers are focusing on reformulating popular drugs as well as developing remedies for symptom mitigation and neuroprotection.

To promote patient outreach, market players have opportunities in the newer levodopa formulations and drug delivery systems, as well as advancements in supplementary drugs and non-dopaminergic therapy options which help the market player to grow in these industries continuously.

However, the development of cost-efficient “speciality drugs” mostly biologics drugs for treatment of PD is now trending. This will help the market player to be upfront with the competition.

Additionally, stem cell therapy by using mesenchymal stem cells for Parkinson’s Disease is currently considered experimental. Innovations for the development of complete curable stem cell therapy with lesser side effects and the use of another source of stem cells are the vast market for the key player.

Thus, new drug production, novel therapy, and manufacturing of diagnostic kits are the key drivers behind the market growth and the revenue of the market players. New technologies, regulatory support, initiatives of the government for patient health, and the establishment of new rules and regulations in the research field are also increasing the scope for the market players.

Clinical Assessment-

Establishing and carrying out clinical trials for novel treatments and medications, patient recruitment strategies, regulatory compliance, ensuring positive trial outcomes, etc. are all made easier with the assistance of DiseaseLandscape Insights. The study titles of the currently ongoing clinical trials, together with the phases in which they are currently being done, are provided in the table below.


Phase I

Phase II

Phase III

Phase IV

Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson’s Disease

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease

Effects of Lingzhi on Disease Progression in Patients with Untreated Early Parkinson’s Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Median Effective Concentration (EC50) of Dexmedetomidine in Deep Brain Stimulation Implantation of Patients with Parkinson’s Disease

High Fiber in Parkinson’s Disease

Effect of Doxycycline in Levodopa Treated Parkinson’s Disease Patients: Randomized, Double-Blind, Placebo-Controlled Trial

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson’s Disease

stradefylline Effect on Parkinson’s Disease Tremor, Motor Symptoms and Non-motor Symptoms

Responders to Metronome-based Rhythmic Auditory Cueing in Parkinson’s Disease

A Phase 2 Study of IkT-148009 in Untreated Parkinson’s Disease

Apomorphine Pump in Early Stage of Parkinson’s Disease

Clinical Study of Stalevo in the Treatment of Early Parkinson’s Disease

Brain Small Chain Fatty Acid Metabolism in Parkinson’s Disease: Tributyrin Supplementation

Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients with Parkinson’s Disease

Long-Term Aerobic Exercise to Slow Progression in Parkinson’s Disease

Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson’s Disease

Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson’s Disease-affected Patients

Effect of Folic Acid on Motor Aspects of Daily Living and Oxidative Stress in Levodopa Treated Parkinson’s Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Clinical Study Evaluating the Efficacy and Safety of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson’s Disease

Pharmacokinetic Study of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patient with Parkinson’s Disease Under Stabilized Treatment

A Phase 1b, Adaptive, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Investigate the Safety, Tolerability Pharmacokinetics, Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease

A Randomized, Double-Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients with Mild to Moderate Parkinson’s Disease Dementia

CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson’s Disease

CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson’s Disease Psychosis (C-SAPP)


There are different market scenarios with respect to countries/regions for Parkinson’s Disease-specific diagnostics and medications. Owing to the disease's modest impact & the challenges associated with the commercial viability of treating diseases have generally shown different national investments in Parkinson’s Disease-specific treatments.

DLI aids in identifying the target market, driving marketing plans, and keeping market participants informed of emerging trends. DiseaseLandscape Insights also helps manufacturers in developing and implementing effective medicines to halt and control Parkinson’s Disease outbreaks.

Additionally, DLI provides comprehensive healthcare market analysis that provides the strategic expertise required to start and maintain a healthcare business. We also assist industry stakeholders in making informed and successful business decisions.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape